Umbralisib is indicated for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; and adults with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific types of...

2022年6月13日 · 出于安全关切，美国食品和药物管理局（FDA）撤回了对癌症药物Ukoniq厄布利塞（umbralisib乌帕利斯）的批准。 厄布利塞Ukoniq曾被批准用于治疗两种特定类型的淋巴瘤：边缘区淋巴瘤（MZL）和滤泡性淋巴瘤（FL）。 来自UNITY-CLL临床实验的最新发现继续展现出在接受Ukoniq厄布利塞的患者中有可能增加的死亡风险。...

On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon...

2023年1月11日 · 2021年2月6日，美国FDA加速批准了厄布利塞（umbralisib，商品名：Ukoniq）上市，用于治疗既往接受过至少一种基于抗CD20疗法的复发/难治性边缘区淋巴瘤（MZL）患者，以及既往接受过至少三线全身治疗的复发/难治性滤泡性淋巴瘤（FL）成人患者。

厄布利塞（umbralisib）由TGTherapeutics（中文名：TG治疗公司）研发，是全球上市的第一款PI3Kδ和CK1ε抑制剂，是FDA批准的第64个小分子激酶抑制剂，也是FDA在2021年批准的第2个小分子激酶抑制剂。

Umbralisib (UKONIQ™) is an oral, first-in-class dual phosphatidylinositol 3-kinase delta (PI3Kδ) and casein kinase 1 epsilon (CK1ε) inhibitor being developed by TG Therapeutics for the treatment of various haematological malignancies. In February 2021, umbralisib received its first approval in the U …

Umbralisib is designed to block a protein called PI3 kinase in order to stop cancer growth and cause changes in the immune system that may allow the immune system to better act against cancer cells. Ublituximab is an antibody that attaches to the lymphoma cells and triggers immune reactions that may result in the death of the targeted lymphoma ...

Umbralisib acts against against marginal zone lymphoma by interrupting the PI3K pathway; this is an essential pathway for B-cell receptor signaling responsible for the progression of lymphoma. In addition, Umbralisib inhibits other pathways involved in specific types of lymphoma, including the casein kinase pathway.

厄布利塞(Umbralisib)是一种激酶抑制剂，用于治疗淋巴瘤。 具体适应证如下： 既往接受过至少1种包含抗CD20治疗的复发或难治性边缘区淋巴瘤（MZL）成人患者。